Related Experiment Video

Updated: May 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer

Patricia A Tang1, Daniel Y C Heng

  • 1Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.

Current Oncology Reports
|December 25, 2012
PubMed

Insights

Programmed death 1 (PD-1) pathway blockade enhances antitumor immunity. This review covers PD-1 inhibition in renal cell and prostate cancers, detailing clinical data for specific antibodies.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Programmed death 1 (PD-1) is a T cell receptor that inhibits immune responses.
  • Its ligands, PD-L1 and PD-L2, are crucial in tumor immune evasion.
  • Targeting the PD-1 pathway can overcome cancer-induced immune suppression.

Purpose of the Study:

  • To review the preclinical basis for inhibiting the PD-1 pathway in advanced cancers.
  • To discuss the clinical efficacy and safety of PD-1/PD-L1 inhibitors in renal cell and prostate cancers.

Main Methods:

  • Literature review of preclinical studies on PD-1 pathway inhibition.
  • Analysis of clinical trial data for anti-PD-L1 (BMS-936559) and anti-PD-1 (MK-3475, BMS-936558) antibodies.

Main Results:

  • Preclinical data support PD-1 pathway blockade for enhancing antitumor immunity.
  • Clinical studies demonstrate activity of PD-1/PD-L1 inhibitors in advanced renal cell and prostate cancers.
  • Specific antibodies show varying efficacy and toxicity profiles.

Conclusions:

  • PD-1 pathway inhibition is a promising strategy for treating advanced renal cell and prostate cancers.
  • Further investigation into the clinical activity and toxicity of these agents is warranted.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...